{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:37:47Z","timestamp":1707525467825},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,2]]},"DOI":"10.7759\/cureus.49843","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T23:54:25Z","timestamp":1701561265000},"source":"Crossref","is-referenced-by-count":0,"title":["Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels"],"prefix":"10.7759","author":[{"given":"Kalliopi","family":"Zafeiropoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Kalampounias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodosia","family":"Androutsopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Katsoris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argiris","family":"Symeonidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.65.070196.004101","article-title":"Structure and functions of the 20S and 26S proteasomes","volume":"65","author":"Coux O","year":"1996","unstructured":"Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996, 65:801-47. 10.1146\/annurev.bi.65.070196.004101","journal-title":"Annu Rev Biochem"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biophys-083012-130417","article-title":"Structural biology of the proteasome","volume":"42","author":"Kish-Trier E","year":"2013","unstructured":"Kish-Trier E, Hill CP. Structural biology of the proteasome. Annu Rev Biophys. 2013, 42:29-49. 10.1146\/annurev-biophys-083012-130417","journal-title":"Annu Rev Biophys"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4 A resolution","volume":"386","author":"Groll M","year":"1997","unstructured":"Groll M, Ditzel L, L\u00f6we J, Stock D, Bochtler M, Bartunik HD, Huber R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature. 1997, 386:463-71. 10.1038\/386463a0","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1126\/science.7725097","article-title":"Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution","volume":"268","author":"L\u00f6we J","year":"1995","unstructured":"L\u00f6we J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science. 1995, 268:533-9. 10.1126\/science.7725097","journal-title":"Science"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.7b00252","article-title":"The proteasome in modern drug discovery: second life of a highly valuable drug target","volume":"3","author":"Cromm PM","year":"2017","unstructured":"Cromm PM, Crews CM. The proteasome in modern drug discovery: second life of a highly valuable drug target. ACS Cent Sci. 2017, 3:830-8. 10.1021\/acscentsci.7b00252","journal-title":"ACS Cent Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.40.25200","article-title":"The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing","volume":"272","author":"Heinemeyer W","year":"1997","unstructured":"Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem. 1997, 272:25200-9. 10.1074\/jbc.272.40.25200","journal-title":"J Biol Chem"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1517\/14796694.1.2.161","article-title":"Bortezomib: proteasome inhibition as an effective anticancer therapy","volume":"1","author":"Richardson PG","year":"2005","unstructured":"Richardson PG, Mitsiades C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncol. 2005, 1:161-71. 10.1517\/14796694.1.2.161","journal-title":"Future Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer","volume":"22","author":"Papandreou CN","year":"2004","unstructured":"Papandreou CN, Daliani DD, Nix D, et al.. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004, 22:2108-21. 10.1200\/JCO.2004.02.106","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg P","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, et al.. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997, 89:2079-88.","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01215-5","article-title":"Treatment of higher-risk MDS","volume":"71","author":"Brunner A","year":"2021","unstructured":"Brunner A. Treatment of higher-risk MDS. Clin Lymphoma Myeloma Leuk. 2021, 71:S71-2. 10.1016\/S2152-2650(21)01215-5","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100940","article-title":"Emerging treatments for myelodysplastic syndromes: biological rationales and clinical translation","volume":"4","author":"Rodriguez-Sevilla JJ","year":"2023","unstructured":"Rodriguez-Sevilla JJ, Adema V, Garcia-Manero G, Colla S. Emerging treatments for myelodysplastic syndromes: biological rationales and clinical translation. Cell Rep Med. 2023, 4:100940. 10.1016\/j.xcrm.2023.100940","journal-title":"Cell Rep Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2015.08.010","article-title":"Myelodysplastic syndromes and acute myeloid leukemia in the elderly","volume":"32","author":"Klepin HD","year":"2016","unstructured":"Klepin HD. Myelodysplastic syndromes and acute myeloid leukemia in the elderly. Clin Geriatr Med. 2016, 32:155-73. 10.1016\/j.cger.2015.08.010","journal-title":"Clin Geriatr Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-876888","article-title":"Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis","volume":"133","author":"Fenaux P","year":"2019","unstructured":"Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019, 133:790-4. 10.1182\/blood-2018-11-876888","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26397","article-title":"Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: open-label, dose-selection, lead-in stage of a phase 3 study","volume":"97","author":"Henry DH","year":"2022","unstructured":"Henry DH, Glaspy J, Harrup R, et al.. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: open-label, dose-selection, lead-in stage of a phase 3 study. Am J Hematol. 2022, 97:174-84. 10.1002\/ajh.26397","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma DP","year":"2021","unstructured":"Steensma DP, Fenaux P, Van Eygen K, et al.. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol. 2021, 39:48-56. 10.1200\/JCO.20.01895","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2011.590567","article-title":"Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines","volume":"29","author":"Liesveld JL","year":"2011","unstructured":"Liesveld JL, Rosell KE, Bechelli J, et al.. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. Cancer Invest. 2011, 29:439-50. 10.3109\/07357907.2011.590567","journal-title":"Cancer Invest"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24746","article-title":"An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes","volume":"92","author":"Daher M","year":"2017","unstructured":"Daher M, Hidalgo Lopez JE, Randhawa JK, et al.. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol. 2017, 92:674-82. 10.1002\/ajh.24746","journal-title":"Am J Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1776.1776","article-title":"Reduced proteasomal activity in marrow cells from myelodysplastic syndrome (MDS) patients","volume":"114","author":"Karabina S","year":"2009","unstructured":"Karabina S, Thanopoulou E, Athanasiou SD, Symeonidis A, Zoumbos N. Reduced proteasomal activity in marrow cells from myelodysplastic syndrome (MDS) patients. Blood. 2009, 114:1776. 10.1182\/blood.V114.22.1776.1776","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071898","article-title":"The ubiquitin proteasome system in hematological malignancies: new insight into its functional role and therapeutic options","volume":"12","author":"Di Costanzo A","year":"2020","unstructured":"Di Costanzo A, Del Gaudio N, Conte L, Altucci L. The ubiquitin proteasome system in hematological malignancies: new insight into its functional role and therapeutic options. Cancers (Basel). 2020, 12:1-22. 10.3390\/cancers12071898","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-491944","article-title":"Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling","volume":"122","author":"Hole PS","year":"2013","unstructured":"Hole PS, Zabkiewicz J, Munje C, et al.. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood. 2013, 122:3322-30. 10.1182\/blood-2013-04-491944","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071349","article-title":"Increased oxidative stress in acute myeloid leukemia patients after red blood cell transfusion, but not platelet transfusion, results mainly from the oxidative\/nitrative protein damage: an exploratory study","volume":"10","author":"Czubak-Prowizor K","year":"2021","unstructured":"Czubak-Prowizor K, Trelinski J, Stelmach P, Stelmach P, Madon A, Zbikowska HM. Increased oxidative stress in acute myeloid leukemia patients after red blood cell transfusion, but not platelet transfusion, results mainly from the oxidative\/nitrative protein damage: an exploratory study. J Clin Med. 2021, 10:1349. 10.3390\/jcm10071349","journal-title":"J Clin Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar SV","year":"2005","unstructured":"Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005, 23:630-9. 10.1200\/JCO.2005.11.030","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3034","article-title":"Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome","volume":"15","author":"Ma W","year":"2009","unstructured":"Ma W, Kantarjian H, Bekele B, et al.. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009, 15:3820-6. 10.1158\/1078-0432.CCR-08-3034","journal-title":"Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.05.008","article-title":"Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma","volume":"38","author":"Oldziej A","year":"2014","unstructured":"Oldziej A, Bolkun L, Galar M, Kalita J, Ostrowska H, Romaniuk W, Kloczko J. Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma. Leuk Res. 2014, 38:925-30. 10.1016\/j.leukres.2014.05.008","journal-title":"Leuk Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09153.x","article-title":"Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I\/II study by the GFM","volume":"158","author":"Natarajan-Am\u00e9 S","year":"2012","unstructured":"Natarajan-Am\u00e9 S, Park S, Ades L, et al.. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I\/II study by the GFM. Br J Haematol. 2012, 158:232-7. 10.1111\/j.1365-2141.2012.09153.x","journal-title":"Br J Haematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3109\/10715762.2015.1035268","article-title":"Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: a pilot study","volume":"49","author":"Gon\u00e7alves AC","year":"2015","unstructured":"Gon\u00e7alves AC, Cortes\u00e3o E, Oliveiros B, et al.. Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: a pilot study. Free Radic Res. 2015, 49:1081-94. 10.3109\/10715762.2015.1035268","journal-title":"Free Radic Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222711","article-title":"In vivo cellular imaging pinpoints the role of reactive oxygen species in the early steps of adult hematopoietic reconstitution","volume":"115","author":"Lewandowski D","year":"2010","unstructured":"Lewandowski D, Barroca V, Ducong\u00e9 F, et al.. In vivo cellular imaging pinpoints the role of reactive oxygen species in the early steps of adult hematopoietic reconstitution. Blood. 2010, 115:443-52. 10.1182\/blood-2009-05-222711","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1242\/dev.107086","article-title":"Stem cells and the impact of ROS signaling","volume":"141","author":"Bigarella CL","year":"2014","unstructured":"Bigarella CL, Liang R, Ghaffari S. Stem cells and the impact of ROS signaling. Development. 2014, 141:4206-18. 10.1242\/dev.107086","journal-title":"Development"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.06.028","article-title":"Two to tango: regulation of mammalian iron metabolism","volume":"142","author":"Hentze MW","year":"2010","unstructured":"Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell. 2010, 142:24-38. 10.1016\/j.cell.2010.06.028","journal-title":"Cell"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1079\/pns19870004","article-title":"Free radicals and metal ions in health and disease","volume":"46","author":"Halliwell B","year":"1987","unstructured":"Halliwell B. Free radicals and metal ions in health and disease. Proc Nutr Soc. 1987, 46:13-26. 10.1079\/pns19870004","journal-title":"Proc Nutr Soc"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2014.10.861","article-title":"Iron toxicity and its possible association with treatment of cancer: lessons from hemoglobinopathies and rare, transfusion-dependent anemias","volume":"79","author":"Puliyel M","year":"2015","unstructured":"Puliyel M, Mainous AG 3rd, Berdoukas V, Coates TD. Iron toxicity and its possible association with treatment of cancer: lessons from hemoglobinopathies and rare, transfusion-dependent anemias. Free Radic Biol Med. 2015, 79:343-51. 10.1016\/j.freeradbiomed.2014.10.861","journal-title":"Free Radic Biol Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M110.006924","article-title":"Oxidative stress-mediated regulation of proteasome complexes","volume":"10","author":"Aiken CT","year":"2011","unstructured":"Aiken CT, Kaake RM, Wang X, Huang L. Oxidative stress-mediated regulation of proteasome complexes. Mol Cell Proteomics. 2011, 10:R110.006924. 10.1074\/mcp.M110.006924","journal-title":"Mol Cell Proteomics"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.11.017","article-title":"New insights into transfusion-related iron toxicity: implications for the oncologist","volume":"99","author":"Porter JB","year":"2016","unstructured":"Porter JB, de Witte T, Cappellini MD, Gattermann N. New insights into transfusion-related iron toxicity: implications for the oncologist. Crit Rev Oncol Hematol. 2016, 99:261-71. 10.1016\/j.critrevonc.2015.11.017","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563221","article-title":"Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome","volume":"124","author":"Shenoy N","year":"2014","unstructured":"Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014, 124:873-81. 10.1182\/blood-2014-03-563221","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making","volume":"23","author":"Malcovati L","year":"2005","unstructured":"Malcovati L, Porta MG, Pascutto C, et al.. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005, 23:7594-603. 10.1200\/JCO.2005.01.7038","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro","volume":"58","author":"Horton TM","year":"2006","unstructured":"Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006, 58:13-23. 10.1007\/s00280-005-0135-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01252.x","article-title":"Depletion of L-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes","volume":"83","author":"Park CH","year":"2009","unstructured":"Park CH, Kimler BF, Yi SY, et al.. Depletion of L-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes. Eur J Haematol. 2009, 83:108-18. 10.1111\/j.1600-0609.2009.01252.x","journal-title":"Eur J Haematol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1021\/tx100125t","article-title":"Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury","volume":"23","author":"Bendova P","year":"2010","unstructured":"Bendova P, Mackova E, Haskova P, et al.. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol. 2010, 23:1105-14. 10.1021\/tx100125t","journal-title":"Chem Res Toxicol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/205223-lower-risk-myelodysplastic-syndrome-mds-patients-exhibit-diminished-proteasome-proteolytic-activity-and-high-intracellular-reactive-oxygen-species-ros-levels","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:05Z","timestamp":1707509465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/205223-lower-risk-myelodysplastic-syndrome-mds-patients-exhibit-diminished-proteasome-proteolytic-activity-and-high-intracellular-reactive-oxygen-species-ros-levels"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.49843","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,2]]}}}